Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial

Advances in Therapy 2026

View at publisher
Authors: Qing Yang, Bin Yang, Heng Gu, Liming Wu, Lanying Qin, Lihua Wang, Yumei Li, Lixiong Gu, Zhu Shen, Siping Zhang, Jianyun Lu, Yuling Shi
+13 more Xiaohua Tao, Yong Cui, Shifa Zhang, Hong Ren, Linfeng Li, Xiaoyong Man, Hui Chen, Rong Xiao, Ziliang Yang, Yuanfang Ren, Rouxuan Ye, Haiwei Du, Furen Zhang
DOI: 10.1007/s12325-025-03419-w
Cited by: 1
References: 30

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Hidradenitis Suppurativa and Treatments Inflammatory Bowel Disease

Publication details

Journal / source
Advances in Therapy
Publisher
Springer Science and Business Media LLC
Volume
43
Issue
3
Pages
1274–1289
Publication date
27 January 2026
Language
EN